Adrenocortical carcinoma laboratory findings

Adrenocortical carcinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Adrenocortical carcinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
MRI
CT
Ultrasound
Other Imaging Studies
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Radiation Therapy
Primary prevention
Secondary prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Study
Case #1
Adrenocortical carcinoma laboratory findings On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Adrenocortical carcinoma laboratory findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Adrenocortical carcinoma laboratory findings
CDC on Adrenocortical carcinoma laboratory findings
Adrenocortical carcinoma laboratory findings in the news
Blogs on Adrenocortical carcinoma laboratory findings
Hospitals Treating Adrenocortical carcinoma
Risk calculators and risk factors for Adrenocortical carcinoma laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]

Overview

Some patients with adrenocortical carcinoma may have elevated concentration of serum cortisol, aldosterone, testosterone or estrogen and reduced concentration of plasma renin and potassium.

Laboratory Findings

Laboratory findings that may associate adrenocortical carcinoma are:

• {| class="wikitable" ! ! |- | |adrenal androgens [DHEAS], androstenedione, bioavailable testosterone should be measured in every patient. 17-hydroxyprogesterone serum estradiol in men and postmenopausal women [85]. |- | |fasting blood glucose, serum potassium, cortisol, ACTH (10 pg/mL) 24-hour urinary free cortisol, fasting serum cortisol at 8 AM following a 1 mg dose of dexamethasone at bedtime, |- |exclusion of a pheochromocytoma |metanephrine and normetanephrine in plasma or 24-hour urine and mainly serves to prevent unexpected complications during surgery or treatment (96) |}

• A recent study has shown significant differences in steroid hormone precursor and metabolite profiles in urine of patients with ACC compared with patients with

benign adrenal tumors (95). This study defined the 11-deoxycortisol metabolite tetrahydro-11-deoxycortisol as the most discriminative marker, although the overall profile of several metabolites provided more information.

Low serum aldosterone concentrations, normal or high serum or urinary concentrations of aldosterone precursors [86,87]